ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Endocrine Practice
- Vol. 24 (5) , 405-410
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Clinician’s Guide to Prevention and Treatment of OsteoporosisOsteoporosis International, 2014
- Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: Insights from a phase IV safety trialJournal of Bone and Mineral Research, 2012
- Acute phase response following intravenous zoledronate in postmenopausal women with low bone massBone, 2012
- The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)Journal of Bone and Mineral Research, 2011
- Serum 25(OH)-Vitamin D Level in ChildrenClinical Pediatrics, 2011
- Vitamin D and its emerging role in immunopathologyClinical Rheumatology, 2011
- Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal womenBone, 2011
- No Effect of Rosuvastatin in the Zoledronate-Induced Acute-Phase ResponseCalcified Tissue International, 2011
- Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acidOsteoporosis International, 2010
- The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statinsClinical and Experimental Immunology, 2004